Additional limitations include cross-mechanism grouping; trial outcomes being closer to one for HR OS; and the studies included in the analysis being a heterogeneous mix of MoAs and study designs, with some studies pre-dating 2010 [i.e., before the first trials of PD-1/PD-L1 checkpoint inhibitors in NSCLC (29)]. Here, PDCD1 is linked to non-small cell lung carcinoma.